Abstract
With great interest, we read the paper “GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis” (by Hu XY et al.), which has reached important conclusions that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response in breast cancer. The result is encouraging. Nevertheless, several methodological flaws in this meta-analysis are worth noticing.
Similar content being viewed by others
References
XY H, Huang XY, Ma J, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis. Tumor Biol. 2015. doi:10.1007/s13277-015-4401-3.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F. Evaluating nonrandomised intervention studies. Health Technol Assess. 2003;7(27):iii-x,1–173.
Qi WX, Shen Z, Tang LN, et al. The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. Tumor Biol. 2014;35(8):7675–83.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Rights and permissions
About this article
Cite this article
Qiu, M., Wu, X. & Qu, X. Note of the methodological flaws in the paper entitled “GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis”. Tumor Biol. 37, 12897–12899 (2016). https://doi.org/10.1007/s13277-016-5154-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-5154-3